Stanley Liu, PhD
Ph.D., MD, FRCPC, Scientist
BSc, Biochemistry Honours, Queen’s University, PhD, Dept. of Medical Biophysics, University of Toronto, MD, University of Toronto, FRCPC, Radiation Oncology
• Assistant Professor, Department of Radiation Oncology, University of Toronto
• Clinician-Scientist, Departments of Radiation Oncology and Molecular & Cell Biology, Sunnybrook Health Sciences Centre
Academic & Clinical Interests
• Breast Cancer
• Prostate cancer
Current Research Projects
Dr. Liu’s research goal is to improve treatment outcomes for cancer patients by researching and integrating novel molecular targeted agents with radiotherapy.
Over 50% of cancer patients will receive radiotherapy sometime during their cancer treatment, and thus it is important to research ways to improve the efficacy of this treatment. Targeting the Notch pathway is a promising avenue, since it is known to disrupt tumor blood vessels and reduce tumor initiating cells. His research is based upon the novel finding that tumor regrowth can be profoundly delayed following radiation treatment, by blocking Notch signaling. His laboratory research seeks to further improve this well-tolerated treatment strategy by understanding the cellular mechanisms that make this treatment work, in addition to discovering pathways that the tumor or its surrounding cellular environment (stroma) use to develop resistance to this treatment. This will allow for targeting of key resistance pathways in conjunction with the existing treatment strategy to make it more effective in preventing tumor regrowth.
The ultimate goal of this research is to use these findings to form a framework for a clinical trial testing this modified treatment strategy in cancer patients. We do not foresee this treatment approach being restricted to a given tumor type, and thus would positively impact the outcomes for a wide-range of cancer patients.